Clinical trials: Mantle Cell Lymphoma (MCL)
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
This phase II trial studies how well ultra low dose orbital radiation therapy works in treating patients with stage I-IV low grade (indolent) B-cell lymphoma or mantle cell lymphoma involving the orbit of the eye (space enclosed…
- Conditions
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma
- Trial name
- NCT02494700
- Testing
- External Beam Radiation Therapy, Orbital Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Small Intestine Cancer
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00005639
- Testing
- Azacitidine Injection, sodium phenylbutyrate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma
Non-Myeloablative Allogeneic Stem Cell Transplantation
1. To determine the safety and efficacy of non-myeloablative allogeneic stem cell transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen for patients with advanced or recurrent mantle cell…
- Trial name
- NCT00525876
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003280
- Testing
- rituximab
- Where
- 10 sites in Switzerland
- Volunteers
- 240 people
- Sponsor
- Swiss Cancer Institute
Lymphoma
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00080886
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Nebraska
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem…
- Trial name
- MANGROVE (NCT04002297)
- Testing
- zanubrutinib, bendamustine, rituximab
- Where
- 176 sites in United States, Australia and 20 more
- Volunteers
- 510 people
- Sponsor
- BeOne Medicines
Brain and Central Nervous System Tumors, Breast Cancer
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy for solid tumors or lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Extragonadal Germ Cell Tumor, Infection
- Trial name
- NCT00005590
- Testing
- levofloxacin
- Where
- United Kingdom
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency
Burkitt Lymphoma, Lymphoma, Follicular
A Safety Study of SGN-CD19A for B-Cell Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
- Conditions
- Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
- Trial name
- NCT01786135
- Testing
- SGN-CD19A
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seagen Inc.
Mantle Cell Lymphoma, Lymphoma
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
The purpose of this study is to test the safety of Venetoclax in combination with FDA approved treatments Bendamustine, Rituximab and Ibrutinib (BR-I).
- Trial name
- NCT03295240
- Testing
- BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax)
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mantle Cell Lymphoma
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of…
- Trial name
- PCYC-1104-CA (NCT01236391)
- Testing
- PCI-32765
- Where
- 18 sites in United States, Germany and 2 more
- Volunteers
- 115 people
- Sponsor
- Pharmacyclics LLC.
Lymphoma, Mantle-Cell
Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL
A Czech Lymphoma Study Group, phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine…
- Trial name
- CLSGMCLPOLA (NCT04913103)
- Testing
- Polatuzumab vedotin, Bendamustine Hydrochloride, Rituximab
- Where
- 7 sites in Czechia
- Volunteers
- 21 people
- Sponsor
- Czech Lymphoma Study Group
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Perillyl Alcohol in Treating Patients With Refractory Cancer
Phase I trial to study the effectiveness of perillyl alcohol in treating patients with refractory cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002862
- Testing
- perillyl alcohol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
This research study will be evaluating the safety and efficacy of a study drug called TGR-1202 in combination with a known drug ibrutinib, also known as Imbruvica, as a possible treatment for Chronic Lymphocytic Leukemia/Small…
- Trial name
- NCT02268851
- Testing
- TGR-1202, Ibrutinib
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase I/II trial studies the side effects and the best dose of v-akt murine thymoma viral oncogene homolog (Akt)/mitogen-activated protein kinase 1(ERK) inhibitor ONC201 and to see how well it works in treating patients with…
- Conditions
- Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
- Trial name
- NCT02420795
- Testing
- Akt/ERK Inhibitor ONC201, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
This phase II trial tests the effect of nemtabrutinib in combination with brexucabtagene autoleucel (brexu-cel) in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that…
- Trial name
- NCT07673367
- Testing
- Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma
Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00028665
- Testing
- filgrastim, rituximab, carmustine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Hodgkin Lymphomas, Follicular Lymphomas
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
The study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus rituximab with regard to progression free survival…
- Conditions
- Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas, Lymphocytic Lymphomas
- Trial name
- NCT00991211
- Testing
- Bendamustine, Standard chemotherapy CHOP + Ritiximab
- Where
- Germany
- Volunteers
- 549 people
- Sponsor
- University of Giessen
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial is studying the side effects and best dose of gossypol when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00891072
- Testing
- R-(-)-gossypol acetic acid, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients…
- Conditions
- Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT06784167
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- OHSU Knight Cancer Institute